Status:
COMPLETED
Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment
Lead Sponsor:
Imperial College London
Collaborating Sponsors:
Novartis Pharmaceuticals
Conditions:
Chronic Myeloid Leukemia
Newly Diagnosed
Eligibility:
All Genders
18+ years
Brief Summary
Imatinib has revolutionised the treatment of chronic myeloid leukaemia (CML). The first clinical trials were conducted in 1998 in patients with advanced disease, and by 2002 imatinib was established a...
Detailed Description
We plan to follow prospectively a cohort of CML patients in order to study their compliance to therapy,pharmacological levels of imatinib and the prevalence of side effects. We expect to be able to co...
Eligibility Criteria
Inclusion
- Patients with CML who have been treated with imatinib (Glivec®) within 6 months of diagnosis as first line therapy. Initial therapy with hydroxyurea is permitted.
Exclusion
- Unable to give consent.
- Unable to communicate with the medical and nursing staff
Key Trial Info
Start Date :
January 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT00632255
Start Date
January 1 2008
End Date
May 1 2009
Last Update
July 8 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Haematology Department. Catherine Lewis Centre. Hammersmith Hospital. Du Cane Road.
London, United Kingdom, W12 0HS